


Hepatitis C: State of Medicaid Access Report Card

New Jersey



Grade	Recommendations to Improve Patient Access
A+	<ul style="list-style-type: none"> Continue to ensure broad access to HCV treatment. Continue to ensure transparency and parity across FFS and MCOs regarding HCV coverage criteria.

State Overview

As of August 2025, 1,749,341 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 47,200 people were living with HCV in New Jersey.² New Jersey Medicaid operates a fee-for-service (FFS) program and contracts with managed care organizations (MCOs). As of 2022, all beneficiaries (100 percent), are enrolled in an MCO.³ New Jersey Medicaid contracts with five MCOs: Aetna Better Health of New Jersey (Aetna), Fidelis Care, Horizon NJ Health (Horizon), UnitedHealthcare Community Plan (UHC), and Wellpoint.⁴

New Jersey Medicaid does not use a uniform Preferred Drug List (PDL); each MCO maintains its own PDL.⁵ The PDLs for Aetna⁶, Horizon⁷, UHC⁸, and Wellpoint⁹ include Mavyret and sofosbuvir-velpatasvir. The PDL for Fidelis Care only includes sofosbuvir-velpatasvir¹⁰.

Deductions		Policy
Prior Authorization		The New Jersey Drug Utilization Review Board removed prior authorization requirements in 2024 for treatment-naïve patients with a confirmed hepatitis C diagnosis. ¹¹
Fibrosis Restrictions		New Jersey Medicaid does not impose fibrosis restrictions. ¹²
Substance Use Restrictions		New Jersey Medicaid does not impose substance use restrictions. ¹³
Prescriber Restrictions		New Jersey Medicaid does not impose prescriber restrictions. ¹⁴
Retreatment Restrictions		New Jersey Medicaid does not impose retreatment restrictions. ¹⁵
Access in Managed Care		Aetna, ¹⁶ Fidelis, ¹⁷ Horizon, ¹⁸ UHC ¹⁹ and Wellpoint, ²⁰ appear to follow the same criteria as FFS. UHC asks about the provider’s “specialty,” but does not appear to require a specialist to prescribe treatment. ²¹
Additional Restrictions		The 2024 Protocol for Direct Acting Antivirals for Hepatitis C published by the NJ DURB does not appear to impose any additional restrictions for treatment-naïve patients.
Total Deductions	0	Total Score [100-Deductions] 100
		Grade A+

Contact Your State Officials

Medicaid Office²²: Greg Woods, Assistant Commissioner, Division of Medical Assistance and Health Services

State of New Jersey Department of Human Services Division of Medical Assistance & Health Services, PO Box 712, Trenton, NJ 08625-0712; Telephone: (609) 588-2600

Drug Utilization Review Board (DURB)²³: DURB Secretary, New Jersey DURB, Office of the Medical Director, Division of Medical Assistance and Health Services

PO Box 712, Trenton, NJ 08625; Telephone: (609) 588-2739

Key Sources

Clinical Criteria: New Jersey Drug Utilization Review Board, [Protocol for Direct Acting Antivirals for Hepatitis C \(updated April 2024\)](#)

- ¹ Centers for Medicare & Medicaid Services, Medicaid and CHIP in New Jersey, <https://www.medicaid.gov/state-overviews/stateprofile.html?state=new-jersey>.
- ² HepVu, Local Data: New Jersey State Profile, <https://map.hepvu.org/profiles/state/new-jersey/overview#H0-1-Populations>.
- ³ Kaiser Family Foundation, Total Medicaid MCO enrollment (July 1, 2022), <https://perma.cc/AYQ4-5VVB>.
- ⁴ New Jersey Division of Medical Assistance and Health Services, New Jersey Medicaid & Managed Care, <https://perma.cc/4S7G-QX9F>.
- ⁵ Kaiser Family Foundation, State Medicaid Preferred Drug Lists (Jul. 1, 2019), <https://perma.cc/N5A2-97EE>.
- ⁶ Aetna Better Health of New Jersey Formulary (August 1, 2025), https://ch.aetnabetterhealth.com/content/dam/aetna/medicaid/pdfs/formulary/ABH_New_Jersey_Formulary_.pdf
- ⁷ Horizon Prescription Drug Listing (August 1, 2025), https://www.horizonnjhealth.com/securecms-documents/368/formulary_english.pdf
- ⁸ United Healthcare Community Plan Preferred Drug List (July 1, 2025), <https://www.uhcprovider.com/content/dam/provider/docs/public/commplan/nj/pharmacy/NJ-Preferred-Drug-List-Family-Care.pdf>
- ⁹ Wellpoint Medicaid-Approved Preferred Drug List (August 1, 2025), https://fm.formularynavigator.com/FBO/4/New_Jersey_PDL_English.pdf
- ¹⁰ Fidelis Care, New Jersey Medicaid Comprehensive Preferred Drug List – 2025 (August 1, 2025), https://www.fideliscarenj.com/content/dam/centene/wellcare/nj/pdfs/pdls/NJ_Caid_Prefered_Drug_List_2025_Eng_Spa_R.pdf
- ¹¹ New Jersey Division of Medical Assistance and Health Services, DURB Meeting Summary (Jul. 14, 2021), <https://perma.cc/3C89-3WTV>.
- ¹² New Jersey Division of Medical Assistance and Health Services, DURB Meeting Summary (Jul. 18, 2018), <https://perma.cc/R8JP-XMVQ>.
- ¹³ New Jersey Division of Medical Assistance and Health Services, DURB Meeting Summary (Jul. 22, 2016), <https://perma.cc/4364-SHKY>.
- ¹⁴ New Jersey Division of Medical Assistance and Health Services, DURB Meeting Summary (Jul. 14, 2021), <https://perma.cc/3C89-3WTV>.
- ¹⁵ New Jersey Division of Medical Assistance and Health Services, DURB Meeting Summary (Jun. 22, 2016), <https://perma.cc/5AU5-QV3D>.
- ¹⁶ Aetna Better Health, Protocol for Direct Acting Antiviral Hepatitis C Drugs (April 2024), <https://www.aetnabetterhealth.com/content/dam/aetna/medicaid/pdfs/formulary/guidelines/DAA-Drugs-for-Hep-C-NJ-State-Approved-Protocol-ua.pdf>. See also Pharmacy Prior Authorization, Hepatitis C Medications (6/14/24): https://fr.aetnabetterhealth.com/content/dam/aetna/medicaid/pdfs/formulary/fax-forms/ABH-NJ_Hepatitis_C_Fax_Form-ua.pdf
- ¹⁷ Fidelis Care, Medicaid, Pharmacy Services, Coverage Determination .
- ¹⁸ Horizon NJ Health, Health Services Policies, Hepatitis C Treatment (July 13, 2025), <https://services3.horizon-bcbnsj.com/ddn/NJhealthWeb.nsf>.
- ¹⁹ New Jersey United Healthcare Community Plan, Hepatitis C Prior Authorization Form (July 6, 2022), <https://perma.cc/2JS5-TDCR>.
- ²⁰ Wellpoint Formulary, Clinical Criteria for Mavyret (November 1, 2024), https://fm.formularynavigator.com/FormularyNavigator/DocumentManager/Download?clientDocumentId=4MsyR_qZ_0W2I-iH1h8JmA
- ²¹ New Jersey United Healthcare Community Plan, Pharmacy Resources and Physician Administered Drugs (links to NJ DURB Protocol for Direct Acting Antivirals for Hepatitis C), Pharmacy Resources and Physician Administered Drugs | UnitedHealthcare Community Plan of New Jersey | UHCprovider.com.
- ²² National Association of Medicaid Directors, Medicaid Directors, <https://medicaiddirectors.org/who-we-are/medicaid-directors/>.
- ²³ New Jersey Division of Medical Assistance and Health Services, Department of Human Services, Drug Utilization Review Board (DURB), <http://www.nj.gov/humanservices/dmahs/boards/durb/>.